1. Scrip
  2. >>Business
  3. >>Deals

Helsinn And BridgeBio Ink Infigratinib Cancer Pact

Duo Will Co-develop And Commercialise FGFR1-3 inhibitor In Oncology

 
• By Sten Stovall

Helsinn’s strategic collaboration with BridgeBio Pharma to co-develop and commercialise candidate FGFR1-3 inhibitor infigratinib in oncology will give the Swiss family-owned company its first targeted cancer therapeutic for the US market, its CEO tells Scrip.

Helsinn Handshake
BridgeBio retains full rights to infigratinib for use in skeletal dysplasias • Source: Shutterstock

Switzerland-based Helsinn Group hopes to market its first targeted cancer therapy in the US though a newly agreed global collaboration and licensing pact with BridgeBio Pharma, Inc. to jointly develop and commercialize the latter’s FGFR1-3 inhibitor, infigratinib.

Under the collaboration, announced 31 March, BridgeBio’s affiliate QED Therapeutics and Helsinn plan to co-commercialize infigratinib for oncology and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Deal Watch: AstraZeneca Remains Busy In AI, Via Deals With Immunai, Turbine And Algen

 
• By Joseph Haas and Lisa Takagi

Plus deals involving Takeda/Innovent, Genentech/Ventus, Sanofi/EVOQ, Novo Nordisk/Sumitomo, Lisata/Catalent, Boehringer Ingelheim/Accent, BI/Molcure, tech transfer agreements and more.

Ipsen Boosts Cancer Pipeline With ImCheck Buy

 
• By Kevin Grogan

The Paris-based group is paying €350m upfront to get hold of Marseille-headquartered ImCheck's acute myeloid leukemia candidate.

Failing to Clinch Sale, Galapagos To Wind Down Cell Therapy Business

 
• By Manas Mishra

Galapagos is closing its cell therapy business after a prolonged search for buyers, leading to job cuts and site closures in the US, Netherlands, Switzerland and China.

China’s Next Wave Is First-In-Class Innovation

 
• By Jessica Merrill

Drug development in China was a discussion topic at the BioFuture conference as the country’s R&D investments begin to deliver first-in-class medicines.

More from Business

Industry Excellence Celebrated At Citeline Japan Awards

 
• By Ian Haydock

Excellence, innovation and deal-making across the Japanese biopharma sector were celebrated at the Citeline Japan Awards 2025, held in Tokyo on 21 October.

China’s Next Wave Is First-In-Class Innovation

 
• By Jessica Merrill

Drug development in China was a discussion topic at the BioFuture conference as the country’s R&D investments begin to deliver first-in-class medicines.

Stock Watch: J&J’s $5bn Product Predictions Meet Investor Skepticism

 
• By Andy Smith

Despite announcing sales growth that is currently weathering the storm of one of its biggest losses of exclusivity and a spin-off of its orthopedic division, J&J’s stock price weakened after its earnings announcement. Investors probably wanted more visibility on MFN.